| Your Weekly Dose | Best Vial Size | Why | |-----------------|---------------|-----| | 1-2mg (titration) | 10mg or 12mg | Less waste, used within 28 days | | 4mg (low therapeutic) | 24mg or 30mg | 6-7 weeks supply, best value | | 8mg (mid therapeutic) | 30mg or 50mg | 3-4 weeks supply at good value | | 12mg (maximum) | 50mg or 60mg | 4-5 weeks supply, lowest cost/mg | *Medical disclaimer: Retatrutide is investigational and not FDA approved
GLP-1 agonist FDA-approved once-weekly 0.252.4 mg Dual GIP/GLP-1 agonist FDA-approved once-weekly 2.515 mg Triple agonist (GLP-1/GIP/glucagon) Phase 3 once-weekly 112 mg Dual GLP-1/glucagon agonist Phase 3 once-weekly trial-reported dosing Amylin analog Phase 3 once-weekly 1.24.5 mg HGH fragment preclinical/community daily 300600 mcg NNMT inhibitor preclinical oral 50-150 mg optional SubQ vial math Oral monoamine reuptake inhibitor trial dosing 0.25-0.5 mg daily Tissue Repair & Recovery Peptides Healing-focused compounds studied for tendon, ligament, muscle, and gut tissue repair
These may vary based on the types of ingredients used and your provider
Likewise, with BPC 157 therapy, there was a re-established musclemuscle continuity, and thereby a re-established tendonmuscle continuity as well [43,44,45,46,47,48,93,94,95,96,97]
This raises significant patient safety concerns
